{"id":"cyclosporine","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Ocular burning","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Conjunctival hyperemia","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Discharge","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Epiphora","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Eye pain","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Foreign body sensation","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Stinging","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Visual disturbance","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["BK Polyomavirus Reactivation Nephropathy","Benign intracranial hypertension","Breastfeeding (mother)","Cyclosporine Toxicity","Disease of liver","Disorder of brain","Eye infection","Hyperbilirubinemia","Hypercholesterolemia","Hyperkalemia","Hypertensive disorder","Hypertensive urgency","Hypertriglyceridemia","Hyperuricemia","Hypomagnesemia","Infectious disease","Kidney disease","Liver function tests abnormal","Malignant lymphoma","Metabolic acidosis, normal anion gap, acidifying salts","Neoplasm","Primary malignant neoplasm","Seizure disorder","Thrombotic thrombocytopenic purpura","Toxic nephropathy"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Severe angioedema","drugRate":"","severity":"serious"},{"effect":"Hypersensitivity","drugRate":"","severity":"serious"},{"effect":"Eye swelling","drugRate":"","severity":"serious"},{"effect":"Urticaria","drugRate":"","severity":"serious"},{"effect":"Face swelling","drugRate":"","severity":"serious"},{"effect":"Tongue swelling","drugRate":"","severity":"serious"},{"effect":"Pharyngeal edema","drugRate":"","severity":"serious"},{"effect":"Dyspnea","drugRate":"","severity":"serious"},{"effect":"Superficial injury of the eye","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT00050648","NCT04989491","NCT00567983","NCT00002790","NCT02744872","NCT05398653","NCT05996393","NCT03830255","NCT00723099","NCT07319793","NCT02121847","NCT03844932","NCT00741338","NCT01410448","NCT00005935","NCT06802055","NCT02229955","NCT05579769","NCT00426101","NCT00048165","NCT07366801","NCT01467505","NCT05219656","NCT00755781","NCT01334892","NCT00303667","NCT01613963","NCT00377325","NCT00171509","NCT00080925","NCT00639717","NCT05969743","NCT04597762","NCT01998633","NCT00053014","NCT00944749","NCT00335114","NCT01180036","NCT01901471","NCT00849888","NCT00482053","NCT01222039","NCT03395431","NCT00977977","NCT00349583","NCT00328653","NCT00260208","NCT04023760","NCT06254560","NCT01170351"],"aliases":["Sandimmune","Neoral","Gengraf","Restasis","ciclosporin","ciclosporine"],"patents":[{"type":"Formulation","number":"8980839","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"CEQUA","expiryDate":"2033-08-23"},{"type":"Formulation","number":"9937225","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"CEQUA","expiryDate":"2033-08-23"},{"type":"Method of Use","number":"11413323","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2039-10-11"},{"type":"Formulation","number":"11154513","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2038-11-20"},{"type":"Method of Use","number":"11612658","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2026-01-27"},{"type":"Method of Use","number":"12496326","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2036-09-29"},{"type":"Method of Use","number":"11951153","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"CEQUA","expiryDate":"2037-02-28"},{"type":"Formulation","number":"12059449","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2042-04-01"},{"type":"Formulation","number":"10441630","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"CEQUA","expiryDate":"2033-08-23"},{"type":"Formulation","number":"8298568","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2027-11-03"},{"type":"Formulation","number":"8292129","applicant":"ABBVIE INC","territory":"US","tradeName":"RESTASIS MULTIDOSE","expiryDate":"2031-02-25"},{"type":"Formulation","number":"9132071","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2029-06-02"},{"type":"Formulation","number":"9220694","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2026-01-27"},{"type":"Formulation","number":"9676525","applicant":"ABBVIE INC","territory":"US","tradeName":"RESTASIS MULTIDOSE","expiryDate":"2034-02-07"},{"type":"Formulation","number":"9956289","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2026-01-27"},{"type":"Formulation","number":"10813976","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2037-09-22"},{"type":"Formulation","number":"9669974","applicant":"ABBVIE INC","territory":"US","tradeName":"RESTASIS MULTIDOSE","expiryDate":"2034-05-11"},{"type":"Formulation","number":"7973081","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2026-01-27"},{"type":"Formulation","number":"10918694","applicant":"SUN PHARMACEUTICAL INDUSTRIES LTD","territory":"US","tradeName":"CEQUA","expiryDate":"2037-02-28"},{"type":"Formulation","number":"8561859","applicant":"ABBVIE INC","territory":"US","tradeName":"RESTASIS MULTIDOSE","expiryDate":"2032-04-16"},{"type":"Formulation","number":"8614178","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VEVYE","expiryDate":"2030-12-13"},{"type":"Formulation","number":"8524779","applicant":"HARROW EYE LLC","territory":"US","tradeName":"VERKAZIA","expiryDate":"2026-01-27"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$2.6815/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$979","description":"CYCLOSPORINE 0.05% EYE EMULSION","retrievedDate":"2026-04-07"}],"allNames":"sandimmune","offLabel":[],"timeline":[],"aiSummary":"Cyclosporine (Sandimmune/Neoral) revolutionized organ transplantation after its approval in 1983, discovered by Jean-François Borel at Sandoz. As the first calcineurin inhibitor, it made reliable transplant immunosuppression possible. Available generically, with the ophthalmic form (Restasis) used for dry eye disease.","brandName":"Sandimmune","companyId":"novartis","ecosystem":[],"mechanism":{"target":"Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2","novelty":"","modality":"Cyclic peptide (natural product)","drugClass":"Calcineurin inhibitor (immunosuppressant)","explanation":"Cyclosporine revolutionized organ transplantation by enabling reliable immunosuppression. Discovered in a soil fungus sample by Jean-François Borel at Sandoz, it binds cyclophilin and the complex inhibits calcineurin, blocking T-cell activation and IL-2 production. Before cyclosporine, organ transplant survival rates were poor. It transformed transplantation into a routine procedure and also treats severe autoimmune conditions.","oneSentence":"Calcineurin inhibitor that suppresses T-cell activation by blocking IL-2 transcription, preventing organ transplant rejection.","technicalDetail":""},"commercial":{"revenueYear":2025,"annualRevenue":1866,"revenueSource":"Teva 2026-02-03 (verified from SEC filing)","revenueCurrency":"USD","revenueConfidence":"high"},"references":[],"biosimilars":[],"companyName":"Novartis AG (originally Sandoz)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cyclosporine","indications":{"approved":[{"name":"Kawasaki's disease","diseaseId":"kawasaki's-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Keratoconjunctivitis sicca","diseaseId":"keratoconjunctivitis-sicca","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Cardiac Transplant Rejection","diseaseId":"prevention-of-cardiac-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Kidney Transplant Rejection","diseaseId":"prevention-of-kidney-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Prevention of Liver Transplant Rejection","diseaseId":"prevention-of-liver-transplant-rejection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Severe Recalcitrant Psoriasis","diseaseId":"severe-recalcitrant-psoriasis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tear film insufficiency","diseaseId":"tear-film-insufficiency","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00050648","phase":"Phase 1","title":"Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.","status":"COMPLETED","sponsor":"Rockefeller University","isPivotal":false,"enrollment":20,"indication":"Psoriasis","completionDate":"2008-04"},{"nctId":"NCT04989491","phase":"Phase 4","title":"Multicenter Randomized Two Arms Study Evaluating the Efficacy of Prophylactic Rituximab in Adult EBV Negative Kidney Transplant Recipients on Incidence of EBV Primary Infection and Post-transplant Lym","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","isPivotal":false,"enrollment":120,"indication":"Epstein-Barr Virus Infections","completionDate":"2029-12-01"},{"nctId":"NCT00567983","phase":"Phase 4","title":"Topical Cyclosporine and Disease Progression","status":"COMPLETED","sponsor":"Innovative Medical","isPivotal":false,"enrollment":80,"indication":"Disease Progression, Disease Severity","completionDate":"2008-09"},{"nctId":"NCT00002790","phase":"Phase 1","title":"A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIG","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":0,"indication":"Graft Versus Host Disease, Leukemia","completionDate":""},{"nctId":"NCT02744872","phase":"Phase 4","title":"Prospektivt Randomiseret Dobbeltblindt Placebo-kontrolleret Studie af, Calciumkanalblokade påbegyndt Inden Operation: Med Henblik på at Forebygge Ciclosporin Induceret Nefropati Efter Lungetransplanta","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","isPivotal":false,"enrollment":42,"indication":"Disorder Related to Lung Transplantation","completionDate":"2016-10"},{"nctId":"NCT05398653","phase":"Phase 1","title":"A Multicenter, Randomized, Controlled, Open Phase Ib/ Ⅱ Study Evaluating the Efficacy and Safety of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Primary Membranous Nep","status":"COMPLETED","sponsor":"Beijing Mabworks Biotech Co., Ltd.","isPivotal":false,"enrollment":94,"indication":"Primary Membranous Nephropathy","completionDate":"2025-04-18"},{"nctId":"NCT05996393","phase":"Phase 4","title":"Ciclosporin + Antithymocyte Immunoglobulin + Avatrombpag Versus Ciclosporin + Avatrombpag for the Treatment of Severe Aplastic Anemia in the Elderly","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","isPivotal":false,"enrollment":86,"indication":"Aplastic Anemia","completionDate":"2025-02-27"},{"nctId":"NCT03830255","phase":"N/A","title":"Calcineurin Inhibitors Among Egyptian Renal Transplant Patients: a Pharmacognetic Based Study.","status":"COMPLETED","sponsor":"Helwan University","isPivotal":false,"enrollment":143,"indication":"Renal Transplantation","completionDate":"2020-03-29"},{"nctId":"NCT00723099","phase":"Phase 2","title":"Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":73,"indication":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","completionDate":"2018-07-31"},{"nctId":"NCT07319793","phase":"NA","title":"Clinical Study on Optimized Treatment for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Myeloid Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","isPivotal":false,"enrollment":200,"indication":"Acute Myeloid Leukemia, Myelodysplastic Syndromes (MDS)","completionDate":"2028-06-30"},{"nctId":"NCT02121847","phase":"Phase 4","title":"","status":"COMPLETED","sponsor":"Allergan","isPivotal":false,"enrollment":40,"indication":"Dry Eye Syndromes","completionDate":"2014-09-23"},{"nctId":"NCT03844932","phase":"Phase 2","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Coli","status":"TERMINATED","sponsor":"Sublimity Therapeutics Holdco Limited","isPivotal":false,"enrollment":235,"indication":"Colitis, Ulcerative","completionDate":"2021-04-14"},{"nctId":"NCT00741338","phase":"Phase 1","title":"A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","isPivotal":false,"enrollment":7,"indication":"Mucopolysaccharidosis I","completionDate":"2012-09"},{"nctId":"NCT01410448","phase":"Phase 3","title":"A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","isPivotal":true,"enrollment":383,"indication":"Kidney Transplantation","completionDate":"2015-12"},{"nctId":"NCT00005935","phase":"Phase 2","title":"A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":false,"enrollment":130,"indication":"Aplastic Anemia","completionDate":"2002-03"},{"nctId":"NCT06802055","phase":"Phase 2","title":"Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","isPivotal":false,"enrollment":40,"indication":"Aplastic Anaemia","completionDate":"2027-01"},{"nctId":"NCT02229955","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disea","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","isPivotal":true,"enrollment":86,"indication":"Dry Eye Syndromes","completionDate":"2014-07"},{"nctId":"NCT05579769","phase":"Phase 2","title":"A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Mal","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","isPivotal":false,"enrollment":3,"indication":"Hematologic Malignancy, Myeloid Malignancy","completionDate":"2024-05-08"},{"nctId":"NCT00426101","phase":"Phase 3","title":"HLH-2004 Treatment Protocol","status":"COMPLETED","sponsor":"Karolinska University Hospital","isPivotal":true,"enrollment":368,"indication":"Hemophagocytic Lymphohistiocytosis","completionDate":"2017-12"},{"nctId":"NCT00048165","phase":"Phase 4","title":"A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transp","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":false,"enrollment":434,"indication":"Heart Transplantation","completionDate":"2002-08"},{"nctId":"NCT07366801","phase":"Phase 2","title":"Pilot Study of Co-Infusion of Donor Lymphocytes Enriched With Regulatory T Lymphocytes With Ex-vivo CD3-Depleted Hematopoietic Stem Cell Graft for the Prevention of Graft-versus-Host Disease in Childr","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","isPivotal":true,"enrollment":64,"indication":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk","completionDate":"2028-02-03"},{"nctId":"NCT01467505","phase":"Phase 2","title":"A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Live","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","isPivotal":false,"enrollment":61,"indication":"Hepatitis C","completionDate":"2014-04"},{"nctId":"NCT05219656","phase":"N/A","title":"Long-term Outcome of Patients With Acute Ulcerative Colitis Treated With Cyclosporine Rescue Therapy.","status":"COMPLETED","sponsor":"Tampere University Hospital","isPivotal":false,"enrollment":182,"indication":"Ulcerative Colitis Acute","completionDate":"2022-01-01"},{"nctId":"NCT00755781","phase":"Phase 3","title":"A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lun","status":"COMPLETED","sponsor":"APT Pharmaceuticals, Inc.","isPivotal":true,"enrollment":284,"indication":"Lung Transplant","completionDate":"2011-11"},{"nctId":"NCT01334892","phase":"Phase 2","title":"A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Pre","status":"TERMINATED","sponsor":"Pari Pharma GmbH","isPivotal":true,"enrollment":130,"indication":"Bronchiolitis Obliterans","completionDate":"2014-12"},{"nctId":"NCT00303667","phase":"Phase 1","title":"Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsui","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","isPivotal":false,"enrollment":50,"indication":"Acute Myelogenous Leukemia","completionDate":"2011-03"},{"nctId":"NCT01613963","phase":"N/A","title":"Observational Study of Visual Outcomes in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","isPivotal":false,"enrollment":2000,"indication":"Uveitis, Scleritis","completionDate":"2012-12"},{"nctId":"NCT00377325","phase":"Phase 2","title":"Cyclosporine in the Pharmacotherapy of Psoriasis","status":"WITHDRAWN","sponsor":"University of Rochester","isPivotal":false,"enrollment":0,"indication":"Psoriasis","completionDate":"2013-09"},{"nctId":"NCT00171509","phase":"Phase 4","title":"A Multicenter, Randomized Open-label Pilot Study to Explore the Benefit of a Conversion From a Twice a Day Administration of Cyclosporine Microemulsion to a Once a Day Administration and to Identify t","status":"COMPLETED","sponsor":"Novartis","isPivotal":false,"enrollment":61,"indication":"Liver Transplant","completionDate":"2005-10"},{"nctId":"NCT00080925","phase":"Phase 1","title":"T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","isPivotal":false,"enrollment":20,"indication":"Chronic Myeloproliferative Disorders, Leukemia","completionDate":"2010-12"},{"nctId":"NCT00639717","phase":"Phase 2","title":"Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","isPivotal":false,"enrollment":48,"indication":"Graft Versus Host Disease","completionDate":"2016-04"},{"nctId":"NCT05969743","phase":"Phase 2","title":"Letermovir Prophylaxis for CMV in Patients With Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation: a Proof of Concept Multicenter Study","status":"UNKNOWN","sponsor":"Rabin Medical Center","isPivotal":false,"enrollment":42,"indication":"Graft-versus-host-disease, CMV","completionDate":"2025-07-31"},{"nctId":"NCT04597762","phase":"NA","title":"Effect of Ciclosporin Eyedrops on Ocular Symptoms and Optical Quality in Patients With Sjögren Syndrome","status":"COMPLETED","sponsor":"Hospital Hietzing","isPivotal":false,"enrollment":12,"indication":"Dry Eye Syndromes","completionDate":"2021-03-31"},{"nctId":"NCT01998633","phase":"Phase 2","title":"Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI) (BMT CTN #1204)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","isPivotal":false,"enrollment":47,"indication":"Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection","completionDate":"2016-12"},{"nctId":"NCT00053014","phase":"Phase 2","title":"S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In Fi","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","isPivotal":false,"enrollment":5,"indication":"Leukemia","completionDate":"2006-06"},{"nctId":"NCT00944749","phase":"Phase 2","title":"Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","isPivotal":false,"enrollment":23,"indication":"Anemia, Aplastic, Anemia, Hypoplastic","completionDate":"2016-12"},{"nctId":"NCT00335114","phase":"NA","title":"Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":40,"indication":"Contact Lens Wearers With Dry Eye Syndrome","completionDate":"2006-04"},{"nctId":"NCT01180036","phase":"Phase 2","title":"\"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)\"","status":"COMPLETED","sponsor":"Mayo Clinic","isPivotal":true,"enrollment":130,"indication":"Idiopathic Membranous Nephropathy","completionDate":"2017-10-01"},{"nctId":"NCT01901471","phase":"Phase 2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":0,"indication":"Acute Myocardial Infarction","completionDate":"2015-10"},{"nctId":"NCT00849888","phase":"Phase 1","title":"Phase I Serum-Free Cultured Thymus Transplantation in DiGeorge Anomaly, IND9836","status":"TERMINATED","sponsor":"Sumitomo Pharma Switzerland GmbH","isPivotal":false,"enrollment":2,"indication":"DiGeorge Anomaly","completionDate":"2011-02"},{"nctId":"NCT00482053","phase":"Phase 2","title":"A Phase 2 Study in Poor Risk Diffuse Large B-cell Lymphoma of Total Lymphoid Irradiation & Antithymocyte Globulin Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autol","status":"TERMINATED","sponsor":"Stanford University","isPivotal":false,"enrollment":3,"indication":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin","completionDate":"2010-05"},{"nctId":"NCT01222039","phase":"Phase 1","title":"Multicenter Clinical Trial Phase I/II Randomized, Controlled, for the Evaluation of Safety and Feasibility of Therapy With Two Different Doses of Allogenic Mesenchymal Stem Cells From Adipose Tissue i","status":"COMPLETED","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","isPivotal":false,"enrollment":19,"indication":"Graft Versus Host Disease, Chronic and Expanded Graft Versus Host Disease","completionDate":"2014-06"},{"nctId":"NCT03395431","phase":"NA","title":"The Feasibility of Fingerprick Autologous Blood (FAB) As a Novel Treatment for Severe Dry Eye Disease (DED)","status":"UNKNOWN","sponsor":"Bedford Hospital NHS Trust","isPivotal":false,"enrollment":60,"indication":"Dry Eye Syndromes","completionDate":"2019-07"},{"nctId":"NCT00977977","phase":"Phase 2","title":"Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","isPivotal":false,"enrollment":30,"indication":"Nephrotic Syndrome, Proteinuria","completionDate":"2027-12-31"},{"nctId":"NCT00349583","phase":"Phase 4","title":"Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation","status":"COMPLETED","sponsor":"Innovative Medical","isPivotal":false,"enrollment":0,"indication":"Cataract, Dry Eye","completionDate":""},{"nctId":"NCT00328653","phase":"Phase 2","title":"Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emuls","status":"COMPLETED","sponsor":"Santen SAS","isPivotal":true,"enrollment":118,"indication":"Conjunctivitis, Vernal","completionDate":""},{"nctId":"NCT00260208","phase":"Phase 4","title":"A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemu","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","isPivotal":false,"enrollment":361,"indication":"Liver Transplant, Hepatitis C","completionDate":""},{"nctId":"NCT04023760","phase":"Phase 4","title":"Pharmacokinetics of Apixaban and Tacrolimus or Cyclosporine in Kidney and Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Saskatchewan","isPivotal":false,"enrollment":14,"indication":"Pharmacokinetics, Kidney Transplant","completionDate":"2020-03-30"},{"nctId":"NCT06254560","phase":"Phase 2","title":"The Study of Rituximab in the Treatment of Severe Aplastic Anemia With Platelet Transfusion Refractoriness","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","isPivotal":false,"enrollment":20,"indication":"Severe Aplastic Anemia, Platelet Transfusion Refractoriness","completionDate":"2027-12-30"},{"nctId":"NCT01170351","phase":"Phase 3","title":"Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","isPivotal":true,"enrollment":55,"indication":"Autoimmune Hepatitis","completionDate":"2018-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral, Intravenous, Ophthalmic","frequency":"Twice daily","formulation":"Capsule, Oral solution, IV injection, Eye emulsion (Restasis)"},"crossReferences":{"unii":"83HN0GTJ6D","rxcui":"3008","splId":"4bc25aeb-44ca-06b2-e063-6294a90a03c0","chemblId":"CHEMBL406352","pubchemSID":"596030"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Immunology"],"_revenueScrapedAt":"2026-03-31 14:09:32.970459+00","biosimilarFilings":[],"firstApprovalDate":"1983-11-14","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Cyclic peptide (natural product)","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-10-01T00:00:00.000Z","mah":"ABBVIE","brand_name_local":null,"application_number":"NDA050790"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-09-20T00:00:00.000Z","mah":"SUN PHARM","brand_name_local":null,"application_number":"NDA210913"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-06-23T00:00:00.000Z","mah":"HARROW EYE","brand_name_local":null,"application_number":"NDA214965"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-05-21T00:00:00.000Z","mah":"DEVA HOLDING AS","brand_name_local":null,"application_number":"ANDA209811"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-11-28T00:00:00.000Z","mah":"AMNEAL","brand_name_local":null,"application_number":"ANDA211909"},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8524779","territory":"US","patent_type":"Formulation","expiry_date":"2026-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7973081","territory":"US","patent_type":"Formulation","expiry_date":"2026-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9956289","territory":"US","patent_type":"Formulation","expiry_date":"2026-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11612658","territory":"US","patent_type":"Method of Use","expiry_date":"2026-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9220694","territory":"US","patent_type":"Formulation","expiry_date":"2026-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8298568","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-03T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9132071","territory":"US","patent_type":"Formulation","expiry_date":"2029-06-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8614178","territory":"US","patent_type":"Formulation","expiry_date":"2030-12-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8292129","territory":"US","patent_type":"Formulation","expiry_date":"2031-02-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8561859","territory":"US","patent_type":"Formulation","expiry_date":"2032-04-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10441630","territory":"US","patent_type":"Formulation","expiry_date":"2033-08-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8980839","territory":"US","patent_type":"Formulation","expiry_date":"2033-08-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9937225","territory":"US","patent_type":"Formulation","expiry_date":"2033-08-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9676525","territory":"US","patent_type":"Formulation","expiry_date":"2034-02-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9669974","territory":"US","patent_type":"Formulation","expiry_date":"2034-05-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12496326","territory":"US","patent_type":"Method of Use","expiry_date":"2036-09-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11951153","territory":"US","patent_type":"Method of Use","expiry_date":"2037-02-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10918694","territory":"US","patent_type":"Formulation","expiry_date":"2037-02-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10813976","territory":"US","patent_type":"Formulation","expiry_date":"2037-09-22T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11154513","territory":"US","patent_type":"Formulation","expiry_date":"2038-11-20T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11413323","territory":"US","patent_type":"Method of Use","expiry_date":"2039-10-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12059449","territory":"US","patent_type":"Formulation","expiry_date":"2042-04-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"pricingByCountry":[{"country_code":"UN","currency":"USD","price_amount":"979.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Un","currency":"USD","price_amount":"979.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":23,"withResults":9},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}